Register for our free email digests:
Latest From DalCor Pharmaceuticals
Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.
Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.
The commercial future of Merck & Co's CETP inhibitor anacetrapib is still in limbo as the 9% reduction in the risk of CV events seen in REVEAL underwhelms. Filings look unlikely.
The positive top-line results for Merck & Co's cardiovascular outcomes trial for its CETP inhibitor anacetrapib may not be enough to de-risk the class, and questions remain about the level of clinical benefit and the regulatory options.
- In Vitro Diagnostics
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- DalCor Pharmaceuticals
- Senior Management
Robert McNeil, CEO
Michael Dixon, CFO
Donald M Black, MD, CMO
Louise Proulx, PhD, Chief Dev. Officer
- Contact Info
Phone: (514) 564-6474
Sherbrooke St. West, Ste. 408
Montreal, H3A 2R7
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.